Dipeptidyl peptidase-4 inhibitors (DPPIV) or neprilysin (neutral endopeptidase) inhibitors used in the treatment of hypertension can increase the propensity of drug-induced angioedema significantly when combined with ACEi [36–38]. The gene discussed is DPP4; the disease is hypertensive disorder.